Grandbrothers/iStock Editorial via Getty Images
The US FDA has issued a Complete Response Letter to Outlook Therapeutics (OTLK) for its resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) for wet age-related macular degeneration. Shares are down ~80% in after-hours trading Wednesday. The agency said that additional information the company provided
Follow us on Google for the latest stock news
From cryptocurrencies to Hermès Birkin bags, Gen Z investors are on the hunt for unconventional assets that double as status...
Car insurance discounts can make a meaningful difference in what you pay each month. But you may be surprised to...
Israeli drone company Xtend has announced a share merger with JFB Construction Holdings (Nasdaq: JFB), which will see the...
I will provide more detail on our outlook later in the call. Please go to slide four. Let us take...
Newsmakers of D-StreetIndian equity benchmarks ended with gains on Tuesday, recording their second successive positive closing. They were aided by...
One could argue that last week’s surprisingly robust jobs report has made Jerome Powell’s job harder, as it defies the...
Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.
